Article
US FDA extends review for GSK-owned Sierra's blood cancer therapy
Rating:
0.0
Views:
35
Likes:
1
Library:
1
GSK Plc said on Friday the U.S. Food and Drug Administration (FDA) has extended the review period by three months for a drug the British drugmaker gained through its $1.9 billion buyout of Sierra Oncology last year.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value